Novel strategies for assessing platelet reactivity

Mohammad Algahtani and Stan Heptinstall

Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Queens Medical Centre, Nottingham, NG7 2UH, U.K.

Corresponding author: stan.heptinstall@nottingham.ac.uk

Abstract

There are many approaches to assessing platelet reactivity and many uses for such measurements. Initially, measurements were based on the ability of platelets separated from other blood cells to aggregate together following activation with an appropriate ‘aggregating agent’. Later, measurements of platelet aggregation in blood itself were performed, and this led to a point-of-care approach to platelet function testing. Measurement of secretory activity through the appearance of the activation marker P-selectin on platelets now provides an alternative approach, which enables remote testing. Measurement of vasodilator-stimulated phosphoprotein phosphorylation is also moving toward application in situations remote from the testing laboratory. Here we provide an overview of the various approaches that are now available, assess their advantages and disadvantages, and describe some of the clinical situations in which they are being used.

Keywords

aspirin, flow cytometry, light transmission aggregometry (LTA), multiplate electrode aggregometry (MEA), P-selectin, P2Y12 antagonists, platelet aggregation, platelet reactivity, VASP phosphorylation, VerifyNow

Platelet reactivity is a broad term indicating the degree of the response of blood platelets to an external stimulus, usually an ‘aggregating agent’. Platelet reactivity can be measured in many different ways and the purpose of this review is to summarize the approaches, with an emphasis on the newer approaches that are becoming available.

Platelets play an important role in the hemostatic process [1,2]. They contribute to the formation of a hemostatic plug that serves to prevent blood loss from injured blood vessels. The hemostatic plug contains thousands of platelets that have aggregated together within a network of fibrin. However, platelets also contribute to the generation of a thrombotic mass in a coronary or cerebral artery or in an artificial stent leading to blockage and resulting in conditions such as heart attack, stroke and stent thrombosis [3,4]. A thrombus is also composed of platelet aggregates within a fibrin network. So thrombus formation can thus be considered to be hemostasis in the wrong place.
It is believed that aggregating agents that are newly released into the arterial circulation or become newly exposed on damaged tissue or on atherosclerotic plaque bring about the platelet aggregation that contributes to the participation of platelets in hemostasis and thrombosis. Some important aggregating agents are collagen, thrombin, ADP and thromboxane A2 (TXA2). These activate platelets through receptors for these agents on the platelet surface. Measurements of platelet reactivity have served to quantify the effects of these and other aggregating agents on platelets. They have also served to quantify the degree of inhibition of platelet activity brought about by pharmacological agents known as ‘antiplatelet agents’, some of which are now used routinely as medicines [5].

There is a general concept that a pronounced platelet response to an aggregating agent is associated with an increased risk of thrombosis and that a low platelet response is associated with bleeding and bruising. Identification of congenital deficiencies in platelet function has helped explain bleeding diatheses and the importance of platelet function in the hemostatic process [6].

Patients with high residual platelet activity despite treatment with antiplatelet agents are at higher risk of future thrombotic events [7]. Also, excessive inhibition of platelet reactivity by antiplatelet agents can be associated with excessive bleeding with implications for surgical interventions. Consequently, there is now the concept of using measurements of platelet reactivity to identify a ‘therapeutic window’ in patients, so as to reduce the risk of a thrombotic event without increasing the risk of bleeding [8–10].

**Approaches to assessment of platelet reactivity**

Many years ago, it was discovered that adding ADP to platelet-rich plasma (PRP) caused platelets to clump together [11]. PRP is obtained when fresh blood, to which an anticoagulant such as sodium citrate has been added to stop the blood from clotting, is centrifuged slowly for about 10 min to remove the red cells and white cells. Within a few seconds of adding ADP or indeed any other aggregating agent to a stirred sample of PRP, the turbidity starts to reduce and within a few minutes the PRP becomes virtually clear. This is a consequence of the individual platelets clumping together to form aggregates of nearly all the platelets that are present. The clumps become so large that they can be seen easily with the naked eye.

Sometimes, the platelet aggregation is irreversible and sometimes it is reversible, in that the aggregation is followed by disaggregation. The type of response is dependent on the absence or presence of pathology in the volunteer or patient being investigated. For example, it can be reduced or absent in patients with bleeding disorders and can be excessive in some patients who are at high risk of thrombosis. It is also dependant on the type and concentration of the aggregating agent used, and on the presence or otherwise of a drug designed to inhibit the platelet response.

The ‘clearing’ of the PRP as aggregation progresses became the basis for measurement of platelet aggregation, hence ‘light transmission aggregometry (LTA)’ or ‘turbidimetry’ in which the ‘clearing’ of the PRP was monitored by detecting the amount of light transmitted through the stirred sample of PRP. The equipment that is used for stirring the PRP and for monitoring the changes in light transmission that occur is known as an
aggregometer. LTA is still referred to as the 'gold standard' for measurements of platelet aggregation or platelet reactivity [12]. This is despite additional approaches to measurement of platelet aggregation that have appeared over the years.

Measurement of platelet aggregation as a means of assessing platelet reactivity is attractive in that it is the formation of clumps of platelets (platelet aggregates) in response to an external stimulus that is a major contributor to the formation of a hemostatic plug formation or a thrombus. The aggregated platelets together with fibrin, the end product of the coagulation cascade, provide structure and stability.

The main external stimuli involved in hemostatic plug and thrombus formation are collagen and thrombin. Collagen is exposed on damaged or diseased blood vessels. Thrombin forms as a consequence of tissue factor exposure and also of platelet adherence to leukocytes to produce platelet–leukocyte conjugates that display tissue factor. Interaction with collagen or thrombin also leads to synthesis of TXA2 from arachidonic acid (AA) liberated from phospholipids within the activated platelets, and also secretion of the contents of storage granules that include ADP. The TXA2 and the ADP contribute further to the platelet aggregation [2,5].

The problems with measurement of platelet aggregation using the LTA approach are threefold. First, the measurements are made in PRP; this is considered to be less physiological compared with blood itself. Second, the number of platelets in the PRP (and hence the turbidity of the sample) varies from patient to patient. Third, the approach requires prompt access to a laboratory with the appropriate equipment and expertise for the measurements to be performed.

Newer approaches to measuring platelet aggregation focus on whole blood, rather than PRP, and include Multiplate Electrode Aggregometry (MEA; a type of impedance aggregometry), VerifyNow (a turbidimetric approach that involves adding fibrinogen coated beads to whole blood) and approaches based on platelet counting.

Platelet aggregation is only one platelet response to an external stimulus. Platelets are complex organelles present in blood in high numbers that, as already mentioned, can be induced to synthesize molecules such as TXA2 and to secrete the contents of intracellular granules including ADP. P-selectin, that forms part intracellular granules known as α-granules, appears on the platelet surface following platelet activation and mediates platelet–leukocyte conjugate formation leading to enhanced generation of thrombin and subsequent fibrin formation. In addition, following an external stimulus there are biochemical changes in platelets that can be quantitated, such as phosphorylation of vasodilator-stimulated phosphoprotein (VASP). Some of these approaches have the advantage of being performed remotely from the testing laboratory with no need for specialist equipment or technical expertise close at hand.

**Methods based on measurements of platelet aggregation**

**Light transmission aggregometry**

Although LTA can no longer be considered a novel strategy, it formed the basis for the methods that came later on, and as previously mentioned, is still considered to be the
The aggregating agent under investigation is added to a stirred sample of PRP in an aggregometer, and the aggregation is quantitated by the increase in light transmittance that occurs. Typical aggregating agents tested include ADP, epinephrine, collagen, AA and thrombin. With regard to thrombin, this is often replaced by a thrombin receptor activation peptide that has the advantage of activating the platelet without also initiating the coagulation cascade by converting fibrinogen to fibrin. The antibiotic, ristocetin is sometimes used for some diagnostic purposes.

For many years, the test has been used to look for defects in platelet aggregation that might explain enhanced bruising or bleeding in a patient. For example, deficiencies in the aggregation response to ADP and most other aggregating agents are indicative of a condition known as Glanzmann’s thrombasthenia brought about by absent or abnormal glycoproteins (GPs) known as GPIIb and GPIIIa on platelets; the GPs need to be present as a complex (the GPIIb/IIIa complex) for platelet aggregation to occur. Platelet activation is accompanied by a rearrangement in the 3D structure of GPIIb/IIIa such that it binds fibrinogen, which then links adjacent-activated platelets together. An absent response to the antibiotic ristocetin is indicative of the Bernard–Soulier syndrome, brought about by the absence or change in another GP complex GPIb/IX/V that is needed for a normal interaction of platelets with the von Willebrand factor in blood plasma; interaction with the von Willebrand factor forms one of the mechanisms through which platelets adhere to exposed collagen [13].

Numerous studies have identified the pharmacological effects of different agents and drugs on platelets. For example, aspirin inhibits aggregation brought about by AA as it blocks the cyclo-oxygenase involved in converting this into TXA2. Clopidogrel and newer P2Y12 antagonists, such as prasugrel, ticagrelor and cangrelor reduce the extent of the platelet aggregation brought about by ADP by interfering with the ability of ADP to interact with P2Y12 receptors on the platelet surface [5].

An example of the use of LTA to assess the impact of different doses of the newly developed drug, AZD6140, in comparison with a standard dose of clopidogrel in patients with atherosclerosis is the DISPERSE study [14]. This is mentioned specifically here because this was a landmark study that clearly demonstrated differences in the rate of onset of inhibition of platelet aggregation by a new orally administered P2Y12 antagonist compared with clopidogrel, differences in degree of inhibition of platelet aggregation, and also differences in the rate of recovery when the drug was withdrawn. The drug in question became known later as ticagrelor. Both prasugrel and ticagrelor are now deemed to be much more effective overall than clopidogrel as inhibitors of platelet aggregation and this translates into more effective antithrombotic therapy, albeit with an increased risk of depressed hemostasis and thus, an increased risk of bleeding [7].

Some antiplatelet agents appear to be much more effective as inhibitors of platelet aggregation after administration to some patients compared with others, and it is this variability in effectiveness that may make the drug clopidogrel less effective as a medicine compared with other P2Y12 antagonists. Despite this, clopidogrel is still widely used as a means of treating patients with a high risk of thrombosis [15]. One reason for variability in the patient response to clopidogrel is that there are genetic differences in
the CYP450 enzymes responsible for converting clopidogrel (which is a prodrug) into its active metabolite [16,17]. Others may include accelerated platelet turnover, upregulation of the P2Y$_{12}$ pathways, high baseline platelet reactivity, poor compliance, underdosing and drug–drug interactions [18]. Many clinical studies have demonstrated that high residual platelet aggregation in response to ADP, despite treatment with the P2Y$_{12}$ antagonist clopidogrel, is associated with further ischemic outcomes [7,16].

As stated above, the newer versions of this class of drug are much less variable in their effectiveness as inhibitors of platelet reactivity. The frequency of ‘nonresponse’ to aspirin, another drug that is very widely used in patients with atherosclerosis, as judged by a lack of effect of the drug on AA-induced platelet aggregation, is also much lower than that seen with clopidogrel [19].

Usually, LTA is used to study platelet aggregation in small samples of PRP stirred in an aggregometer. More recently, LTA has been successfully used in the Optimul Assay in which the effects of multiple platelet agonists have been tested in parallel in PRP obtained from patients with bleeding disorders. The approach involves agitating small volumes of PRP in a 96-well platelet with measurement of the changes in light absorbance using a platelet reader. The approach proved to be comparable with other testing procedures [20].

**Multiplate electrode aggregometry**

Impedance aggregometry was introduced by Cardinal and Flower [21]. It is based on the measurement of the electrical resistance between two electrodes immersed in stirred whole blood. As platelets aggregate and bind to the electrodes, there is a change in electrical impedance that corresponds to the degree of aggregation that has occurred. A clear advantage of using whole blood rather than PRP is that a centrifugation step is not required, thus simplifying the measurement and opening up the possibility of a point-of-care approach to measurement of platelet reactivity.

The version of impedance aggregometry that has been used most in recent years is MEA (Multiplate Analyzer, Roche, Munich, Germany), which uses two sets of electrode pairs, so that a double determination is performed on each sample to ensure measurement repeatability. The advantage compared with LTA is that the measurements are performed in blood rather than PRP. The main disadvantage is that, as for LTA, prompt access to a laboratory and appropriate expertise is still needed.

In the literature, there are many positive examples of the use of MEA. For example, MEA was used to investigate the inherited bleeding disorder Glanzmann’s thrombasthenia where markedly reduced responses to a number of platelet-aggregating agents were evident, in the same way as seen with LTA [22,23]. The approach also proved as useful as LTA for measuring the degree of inhibition of platelet aggregation by the antiplatelet agents aspirin and clopidogrel in preoperative patients scheduled for elective cardiac surgery [24].

Clopidogrel is one of the most commonly used P2Y$_{12}$ antagonists. However, as discussed above, the pharmacodynamics response varies with a significant number of patients presenting with high platelet reactivity despite the treatment. And as with
measurements performed using LTA, high residual platelet reactivity as measured with MEA is associated with increased risk of further ischemic outcomes. The practical usefulness of the MEA approach was demonstrated in a study performed by Hazarbasanov et al. [25] in which MEA was used to identify patients undergoing a percutaneous coronary intervention (PCI) who still demonstrated high platelet reactivity despite treatment with clopidogrel; in this case, increasing the dose of clopidogrel seemed to bring about favourable outcomes.

In another study, the MADONNA study, patients in one hospital received additional antiplatelet therapy (guided by investigations using the MEA) while those in another hospital did not. The study demonstrated the benefit of tailored antiplatelet therapy in that stent thrombosis and acute coronary syndrome occurred significantly less often in the guided group [26]. In another study, low platelet reactivity identified using the MEA seemed to be as effective as assessment of CYP450 variants in identifying patients undergoing coronary stent placement with an increased bleeding risk, although in this case the expected relationship between high platelet reactivity and stent thrombosis was not evident [27].

Currently, the benefit of MEA testing to guide treatment is being tested in the TROPICALACS trial that is investigating the clinical and health-economic impact of tailored antiplatelet therapies in PCI [28].

**VerifyNow**

VerifyNow (Accumetrics, Inc, CA, USA) is a testing approach that is specifically used for point-of-care measurement of inhibition of platelet aggregation by aspirin, P2Y$_{12}$ antagonists such as clopidogrel, and also antiplatelet agents known as GPIIb/IIIa antagonists. As with LTA and MEA, ADP is used to activate the platelet to monitor clopidogrel therapy, while AA is used to monitor aspirin therapy. A thrombin receptor activation peptide is used to monitor the effects of a GPIIb/IIIa antagonist. Following activation by the agonist, fibrinogen-coated beads are able to bind to the activated platelet through GPIIb/IIIa on the platelet surface to form an agglutinate and the resulting ‘clearing’ of the sample is measured by turbidimetry. The tests are fully automated for measurements made at the point of blood collection and there is no requirement for a specialized laboratory and/or specially trained expert personnel.

As with LTA and MEA, the VerifyNow system has been used to demonstrate the prognostic significance of high residual platelet function in patients treated with clopidogrel. For example, a higher risk of stent thrombosis and myocardial infarction was evident in association with high residual platelet reactivity in the ADAPT-DES study [29]. In a further analysis of the same study, low residual platelet reactivity in clopidogrel treated patients was demonstrated to be associated with increased bleeding [30]. Low residual platelet reactivity was also shown to be associated with bleeding in a study of patients undergoing PCI [31]. In view of such findings, VerifyNow has also been tested as a means of predicting bleeding in clopidogrel-treated patients undergoing coronary artery bypass grafting and a relationship between lower platelet reactivity and increased bleeding has been established in two pilot studies that have been performed [32,33].
In view of higher rates of thrombotic consequences in patients with high residual platelet reactivity in clopidogrel-treated patients, two large studies were performed in which the intention was to use the VerifyNow system to demonstrate the benefit of adjusting antiplatelet therapy in patients undergoing PCI for stable coronary artery disease. Unfortunately, the GRAVITAS study did not demonstrate any reduction in serious cardiovascular outcomes in patients with high on-treatment platelet reactivity who received a higher dose of clopidogrel consequent to testing [34]. It has been argued that simply increasing the dose of clopidogrel is insufficient to achieve the effect that was desired, and that this is the main reason for the negative outcome of this study [35]. In the second study, TRIGGER-PCI, the more potent P2Y₁₂ antagonist prasugrel was used in place of clopidogrel to effect greater inhibition of platelet function in patients with high residual platelet reactivity, but this trial also failed to meet the desired outcome. The study was terminated prematurely due to a lower than the expected event rate in the relatively low-risk patients who were recruited into this study [36].

Very recently, it was reported that VerifyNow testing to optimize treatment with prasugrel in elderly patients with acute coronary syndromes in the ANTARCTIC trial failed to provide any benefit in terms of a composite of cardiovascular death, myocardial infarction, stroke, stent thrombosis, urgent revascularization and bleeding complication at 1 year [37].

More positively, clopidogrel non-responders identified using the VerifyNow system who then received the GPIIb/IIIa antagonist tirofiban in addition to standard therapy with aspirin and clopidogrel went on to experience fewer subsequent incidents of myocardial infarction [38,39].

**Platelet counting**

When platelets aggregate together the number of single platelets in the blood falls and this fall in platelet number can be used as a measure of the extent of platelet aggregation that occurs. Platelet counting can be performed using a commercial whole blood cell counter that utilizes impedance counting technology, or using a flow cytometer [40]. The use of a fixative that stops the aggregation at the point at which a measurement is required, is an advantage if a platelet counting device is not immediately available for the counting to be performed [41,42,43].

Plateletworks (Helena Laboratories, TX, USA) is an approach to the measurement of platelet aggregation in which platelets in blood are stimulated with ADP or collagen following which platelet counting is performed. Counts are compared with those prior to adding the aggregating agent. Immediate platelet counting is essential as no fixative is employed. The advantages over other approaches are that no sample preparation is needed; the measurements are performed on whole blood using preloaded baseline and platelet agonist tubes. Also it is a simple and rapid procedure and platelet count and aggregation results are available immediately provided a platelet counting device needs to be available. In a comparison with LTA, there was good agreement when used for monitoring the inhibitory effects of clopidogrel, although the necessity for immediate platelet counting was noted [44], which would have been due to the instability of the unfixed platelet aggregates in the blood.
While not yet as widely used as other approaches to studying platelet reactivity in clinical situations, high on-treatment ADP-induced platelet reactivity in patients taking clopidogrel demonstrated using the Plateletworks approach has been shown to be predictive of subsequent myocardial infarction and of rehospitalization within 3 months of testing [45].

Adding a fixative to the blood at the precise point at which a measurement of platelet aggregation is required, has the advantage of introducing a period of time between experimentation and platelet counting that obviates the need for the immediate availability of a platelet counting device. It also provides the opportunity for remote testing with the actual platelet counting being performed up to several days after experimentation, thus opening up the number of different types of location for the testing. The fixative AGGFix (Platelet Solutions Ltd, Nottingham, UK) offers such an opportunity.

A good example of the use of AGGFix to measure platelet aggregation remotely is a study that was performed in Iceland with the platelet counting performed in the UK. The circumstance was a clinical trial in which a new antiplatelet agent, an EP3 receptor antagonist, was administered to volunteers with and without clopidogrel or clopidogrel and aspirin, after which the effectiveness of the drugs as inhibitors of platelet aggregation was assessed [46]. More recently, AGGFix has also been used successfully for assessment of platelet aggregation using the platelet counting approach in blood placed in 96-well plates and also, in parallel, to assess the degree of platelet–leukocyte conjugate formation that occurred, assessed by flow cytometry [47].

Methods based on measurements of platelet activation markers

As mentioned above, platelet aggregation is only one platelet response to an external stimulus. Synthesis of TXA2, release of ADP and the appearance on the platelet surface of activation markers such as P-selectin also provide means of assessing platelet reactivity. Measurements of TXB2, the stable breakdown product of TXA2 and also of TXA2 metabolites have provided a direct means of assessing the activity of the cyclooxygenase in platelets and particularly the effect of aspirin on this. Measurements of secreted ADP have been performed in parallel with LTA in a device known as a lumiaggregometer and this has proved particularly useful in studies of defects in the platelet storage pool in patients leading to pronounced bruising and bleeding. Once again, however, the ready availability of specialist equipment and expertise are required.

The appearance on the surface of platelets of markers of platelet activation can be demonstrated and quantitated using flow cytometry [48] and these include P-selectin that is translocated to the platelet surface from α-granules within platelets. Platelets can be activated in whole blood using an appropriate aggregating agent, either in blood that is left unstirred or that contains an additional agent such as EDTA to prevent platelet aggregation occurring. The amount of P-selectin on activated single platelets is then measured by flow cytometry. The use of a fixative added to the blood following platelet activation successfully extends the time between experimentation and P-selectin analysis to several days, thus allowing for remote platelet function testing. A useful
fixative for this purpose that is commercially available is PAMFix (Platelet Solutions Ltd) [49].

There is now good progress in developing tests for particular purposes based on measurement of P-selectin and these include Aspirin Kits (for determining the effects of aspirin on platelet reactivity), P2Y12 kits (for determining the effects of drugs such as clopidogrel, prasugrel, ticagrelor and cangrelor on platelet reactivity) and kits for screening patients for evidence of platelet dysfunction without the need for referral to a specialist facility [49,50].

An assessment of platelet functional defects in patients with easy bruising and bleeding based on the appearance of activation markers on platelets was performed as part of the Genotyping and Phenotyping of Platelets study. In this study, both P-selectin (as a marker of α-granule secretion) and CD63 (as a marker of dense body secretion) were measured on platelets stimulated with three different aggregating agents, and the results compared with those using lumiaggregometry. There was a good agreement between lumiaggregometry and the results of the P-selectin testing, with diagnosis being concordant in 84% of cases [51,52].

In another study, P-selectin measurement using the P2Y12 kit identified a group of patients with acute coronary syndromes in whom high platelet reactivity was retained despite treatment with clopidogrel and were demonstrated to be at significantly higher risk of experiencing a further acute thrombotic event [53], thus demonstrating concordance between P-selectin measurements and other approaches to the measurements of platelet reactivity. Also it was demonstrated that treatment of patients with acute coronary syndromes with the P2Y12 antagonist prasugrel generates a higher degree of inhibition of P-selectin expression than clopidogrel except, interestingly, in patients with hypertension [54]. The P-selectin approach has also been used to assess platelet reactivity in patients with acute stroke [55]. The study demonstrated the effects of antiplatelet therapy being taken on admission with acute stroke on the measurements performed as part of the TARDIS study [Bath PM et al. Remote assessment of platelet function in patients with acute stroke or transient ischaemic attack, Submitted (2016)]. The approach has also been used to assess the residual effects of aspirin in surgical patients from whom this antiplatelet agent had been withdrawn [56]. The approach is also finding a use for determining the efficacy of antiplatelet agents in veterinary medicine [57].

Platelet activation leads to formation of platelet–leukocyte conjugates in whole blood, largely consequent to P-selectin on the surface of activated platelets interacting with a protein known as PSGL-1 on the leukocytes. Such conjugates can be quantitated using flow cytometry. For testing sites that do not have immediate access to such equipment, the use of a fixative such as AGGFix (Platelet Solutions Ltd) enables testing to be conducted remotely and then transferred to an appropriate laboratory for the flow cytometric analysis. Early results demonstrated increased levels of particularly platelet–monocyte conjugates in association with myocardial infarction [58]. Also the approach has been used to quantitate the effects of antiplatelet drug therapies in volunteers and in patients with stroke [59]. More recently, measurements of platelet aggregation and also platelet–leukocyte conjugate formation have been measured in parallel in the same blood samples in studies involving 96-well plate technology [40].
Parallel studies have also been performed on blood from mice [60]. In a recent review, it was considered that further studies are needed before platelet–leukocyte conjugate formation becomes routinely used in clinical practice [61].

### Methods based on measurements of a cell metabolite

A particular cell metabolite, the levels of which have been exploited as a means of studying platelet activation, is VASP. The level phosphorylated VASP (VASP-P) reflects the level of cyclic nucleotides in platelets (and other cells); in particular, it has been used as a means of determining the effects of agents that both increase and lower the level of cyclic AMP (cAMP) in platelets. cAMP is an important intracellular modulator of platelet reactivity with low levels supporting the platelet response and high levels being inhibitory. An important use of measurement of VASP phosphorylation has been in generating an assay for determining the effectiveness of clopidogrel acting as an antagonist at the P2Y₁₂ receptors on platelets.

One assay (Biocytex, Marseille, France) involves stimulating platelets with prostaglandin E₁ (PGE₁) to raise cAMP and then determining the ability of added ADP to lower that raised level of cAMP acting via the P2Y₁₂ receptor. Good blockade of the receptor following clopidogrel administration, and thus high levels of VASP-P, implies effective treatment with clopidogrel. Because the level of VASP-P is controlled through ADP acting at the P2Y₁₂ receptor and not by any other ADP receptor on the platelet, this approach is deemed to be the only current approach that selectively determines the effectiveness of clopidogrel acting via the P2Y₁₂ receptor. In this particular assay, measurement of VASP-P involves permeabilization of platelets followed by flow cytometric assessment of the level of a fluorescent antibody directed at VASP-P inside the platelets. So, like many other approaches to the measurement of platelet reactivity, direct access to specialist laboratory facilities is required.

Early studies were adjudged to compare very favorably with the VerifyNow and LTA approaches to assess the degree of inhibition brought about by clopidogrel or prasugrel administered to patients with acute coronary syndromes [62,63]. A recent successful application of this technology was to time the onset of P2Y₁₂ receptor blockade after administration of prasugrel and ticagrelor in patients with acute coronary syndromes [64]. Very recently, a study was performed to directly compare the rate of formation of the active metabolite of clopidogrel in treated patients with the effects of the clopidogrel on platelet reactivity determined using the VASP assay and also MEA. It was concluded that the pharmacodynamics effects of the drug determined by the VASP measurements entirely reflected the pharmacokinetic measurements but that the results with MEA were disappointing in this regard [65].

More recently, another approach to measurement of VASP-P has been developed that utilizes VASPFix (Platelet Solutions Ltd), which provides a one-step approach to the measurement [66]. VASPFix includes a lytic agent, glass beads that bind the VASP from the lysed platelets and an appropriate fluorescent antibody to determine the level of VASP-P on the beads. The stability of the treated sample is such that after adding VASPFix to blood or PRP, the level of VASP-P is either determined directly using flow cytometry or the sample is frozen and analysed at a later time. Indeed the measurement
is stable for several months after sample preparation. The approach has been used to assess platelet reactivity in patients taking clopidogrel or prasugrel with similar results being obtained to those using the Biocytex assay. In contrast to the use of PGE1 in the Biocytex assay, the VASPFix assay uses iloprost to raise cAMP in platelets. This is because it is now known that PGE1 acts at EP3 receptors on platelets, as well as the IP receptor, which acts to reduce VASP-P in the same way as ADP acting at the P2Y12 receptor, and this appears to reduce the specificity of a test designed purely to investigate the effects of drugs acting at the P2Y12 receptor [66].

Other approaches to assessing platelet reactivity

The Platelet Function Analyser (PFA)-100 involves passing whole blood at high shear stress through a capillary tube toward an aperture in a collagen-coated membrane, which contains either ADP or epinephrine. The time it takes to occlude this opening is defined as closure time. A high closure time is seen in patients with von Willebrand’s disease reflecting the importance of platelet adhesion to collagen in this particular assay. The assay that includes epinephrine is affected by aspirin treatment but, surprisingly the assay that includes ADP is relatively insensitive to P2Y12 antagonists [67,68]. The approach was deemed useful for determining inhibition of platelet function by aspirin but not clopidogrel when compared with the MEA [69].

To circumvent this lack of sensitivity to P2Y12 antagonists, an additional test cartridge (the INNOVANCE PFA P2Y test cartridge) was introduced in which the ADP is supplemented with PGE1. At least as judged by experiments performed in which a P2Y12 antagonist was added to whole blood in vitro, the INNOVANCE PFA P2Y cartridge appears to be comparable to other currently available tests of platelet reactivity [70,71]. Also the test was able to identify some non-responders to clopidogrel, identified initially using other approaches, in some groups of volunteers and patients of treated with this drug [71,72]. A further report indicated its usefulness in identifying patients with congenital defective responses to ADP [73] and there is also a correlation with CYP450 genotypes in clopidogrel-treated patients [74,75]. The sensitivity of the test is markedly influenced by the nature of the anticoagulant used in obtaining the blood for analysis [70] and it is likely that this should be taken account of in any future studies. Incidentally, a focus on the implications of the anticoagulant used in testing of platelet reactivity globally is a matter that still requires close attention. For example, the MEA currently recommends the use of hirudin in preference to citrate for testing the effectiveness of P2Y12 antagonists where citrate seems to reduce the degree of inhibition of platelet reactivity brought about by such agents [76]. Also, very recently, potential problems have been identified in the routine use of citrate in the VerifyNow assay for measurements performed at a time point very close to venepuncture, which appear to be caused by a ‘stunning’ effect of the citrate on platelet reactivity [77].

Thrombelastography (TEG; Haemonetics Corporation, MA, USA) is a global test of thrombosis, which measures aspects of clot formation in a specially designed device. There were some early encouraging results when ADP-induced platelet–fibrin clot strength was used to serve as a predictor of either ischemic events or bleeding in clopidogrel-treated patients poststenting [78]. However, the approach is still not widely used for studies of platelet reactivity and in a recent study, the TEG results were found not to correlate well with the VerifyNow approach [79]. On the other hand, an
adaptation known as short TEG has recently been used to assess the impact of aspirin and clopidogrel in patients with stent thrombosis and to modify treatments on the basis of the results obtained [80,81]. In addition, the first report of the TEG-6S system has just been published, which is claimed to offer a point-of-care approach to TEG [82]. So far the studies are not large enough for the full impact of these new approaches to be assessed, but there does appear to be some promise here.

Aggreguide (Aggredyne, Inc., TX, USA) is a new point-of-care testing procedure based on light scattering technology that is in the very early stages of evaluation. While it appears to be attractive and easy to use, the first published study in cardiovascular patients showed poor reproducibility with other tests of platelet reactivity [83].

**Final considerations**

There are many different approaches to assessing platelet reactivity. Here, the focus has been on measurements of platelet aggregation using variety of different approaches and on the use of platelet activation markers and a particular cell metabolite. Although not discussed in detail in this review, it is generally considered that the comparability of different testing procedures is sometimes quite disappointing [84]. However, this is against a background of a huge number of variations in the detailed methodologies employed within any one of the approaches used, and uncertainties about the positioning of cutoffs between values that are deemed acceptable and those that are not. Our own experience in developing the newer remote assays based on measurement of P-selectin is that these appear to compare reasonably well with the other technologies for identification of patients with platelet dysfunction [51,52] and also when comparing results obtained for patients taking aspirin, clopidogrel or prasugrel [49].

One of the main problems with platelet function testing in general is the need for specialist equipment and expertise in close proximity to the blood sampling. However, some progress is now being made in the use of fixatives that provide the option of remote testing with no requirement for equipment and expertise at the testing site.

**Future perspective**

Platelet reactivity is measured in freshly prepared blood and historically has relied on the availability of specialized equipment and technical expertise for the measurements to be performed. But recent advances mean that measurement of platelet reactivity is becoming easier. Blood can be activated, stabilized and sent away for analysis without any need for equipment or special expertise at the point of blood sampling. It is anticipated that this will make it easier to assess platelet function in relation to bleeding diatheses consequent to congenital or drug-induced platelet hypoactivity, and also to determine high residual platelet reactivity in patients who are at risk of conditions such as heart attack and stroke, often despite drug treatment. Effective titration of drug treatment could then be a real possibility with more effective P2Y12 antagonists such as prasugrel or ticagrelor used in place of clopidogrel in all patients who need this, and possibly clopidogrel used in place of the more effective agents to avoid bleeding.

**Conclusion**
An overall assessment of current and future approaches to assessing platelet reactivity is provided in Table 1. The table summarizes the various approaches available and identifies their main advantages and disadvantages. It can be seen that measurements of platelet aggregation are gradually giving way to alternative userfriendly methodologies that provide similar information on the degree of platelet activation in a blood sample from individual patients that can be used for diagnostic and drug monitoring purposes. The use of flow cytometry with fixation, which enables remote platelet testing, is moving forward rapidly, while some of the very new approaches require further validation before they will find a place in routine practice.

Financial & competing interests disclosure

S Heptinstall is a founder and a director of Platelet Solutions Ltd., with a shareholding in the company. Platelet Solutions is a spinout company of the University of Nottingham that seeks to expand the possibilities for platelet function testing for use in diagnosis and treatment. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

References

Papers of special note have been highlighted as: • of interest

1 Jurk K, Kehrel BE. Platelets: physiology and biochemistry. *Semin. Thromb. Hemost.* 31(4), 381–392 (2005).

2 Gremmel T, Frelinger AL 3rd, Michelson AD. Platelet physiology. *Semin. Thromb. Hemost.* 42(3), 191–204 (2016).

3 Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. *Hematology Am. Soc. Hematol. Educ. Program* 2011, 51–61 (2011).

4 Papapanagiotou A, Daskalakis G, Siasos G, Gargalionis A, Papavassiliou AG. The role of platelets in cardiovascular disease: molecular mechanisms. *Curr. Pharm. Des.* doi:10.2174/1381612822666160607064118 (2016) (Epub ahead of print).

5 Heptinstall S. Antiplatelet agents: current and novel. In: *Antiplatelet and Anticoagulation Therapy.* Ferro A, Garcia DA, (Eds). Springer, Berlin, Germany, 1–44 (2013).

6 Nurden AT, Nurden P. Congenital platelet disorders and understanding of platelet function. *Br. J. Haematol.* 165(2), 165–178 (2014).

7 Gurbel PA, Tantry US. Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. In: *Antiplatelet and Anticoagulation Therapy.* Ferro A, Garcia DA (Eds). Springer, Berlin, Germany, 45–112 (2013).
8 Tantry US, Bonello L, Aradi D et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. *J. Am. Coll. Cardiol.* 62(24), 2261–2273 (2013).

- Discusses the concept of a ‘therapeutic window’ in patients receiving antiplatelet agents, so as to optimize a reduction in risk of a thrombotic event without increasing the risk of bleeding.

9 Aradi D, Kirtane A, Bonello L et al. Bleeding and stent thrombosis on P2Y$_{12}$-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. *Eur. Heart J.* 36(27), 1762–1771 (2015).

- Discusses the concept of a ‘therapeutic window’ in patients receiving antiplatelet agents, so as to optimize a reduction in risk of a thrombotic event without increasing the risk of bleeding.

10 Campo G, Fileti L, Valgimigli M et al. Poor response to clopidogrel: current and future options for its management. *J. Thromb. Thrombolysis* 30(3), 319–331 (2010).

- Discusses the concept of a ‘therapeutic window’ in patients receiving antiplatelet agents, so as to optimize a reduction in risk of a thrombotic event without increasing the risk of bleeding.

11 Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. *Nature* 194, 927–929 (1962).

12 Frontroth JP. Light transmission aggregometry. *Methods Mol. Biol.* 992, 227–240 (2013).

13 Abbate R, Cioni G, Ricci I, Miranda M, Gori AM. Thrombosis and acute coronary syndrome. *Thromb. Res.* 129(3), 235–240 (2012).

14 Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y$_{12}$ antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. *Eur. Heart J.* 27(9), 1038–1047 (2006).

- It is a good example of the use of light transmission aggregometry in drug assessment in a clinical study.

15 Harrison P. Advances in the monitoring of anti-P2Y$_{12}$ therapy. *Platelets* 23(7), 510–525 (2012).

16 Bonello L, Tantry US, Marcucci R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. *J. Am. Coll. Cardiol.* 56(12), 919–933 (2010).

17 Campo G, Miccoli M, Tebaldi M et al. Genetic determinants of on-clopidogrel high platelet reactivity. *Platelets* 22(6), 399–407 (2011).
18 Campo G, Parrinello G, Ferraresi P et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. *J. Am. Coll. Cardiol.* 57(25), 2474–2483 (2011).

19 Lordkipanidzé M. Advances in monitoring of aspirin therapy. *Platelets* 23(7), 526–536 (2012).

20 Lordkipanidzé M, Lowe GC, Kirkby NS et al. Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. *Blood* 123(8), e11–e22 (2014).

21 Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. *J. Pharmacol. Methods* 3(2), 135–158 (1980).

22 Awidi A, Maqablah A, Dweik M, B'soul N, Abu-Khader A. Comparison of platelet aggregation using light transmission and multiple electrode aggregometry in Glanzmann thrombasthenia. *Platelets* 20(5), 297–301 (2009).

23 Albanyan A, Al-Musa A, Alnouneou R et al. Diagnosis of Glanzmann thrombasthenia by whole blood impedance analyzer (MEA) vs. light transmission aggregometry. *Int. J. Lab. Hematol.* 37(4), 503–508 (2015).

24 Velik-Salchner C, Maier S, Innerhofer P et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. *Anesth. Analg.* 107(6), 1798–1806 (2008).

25 Hazarbasanov D, Velchev V, Finkov B et al. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. *J. Thromb. Thrombolysis* 34(1), 85–90 (2012).

26 Siller-Matula JM, Francesconi M, Dechant C et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. *Int. J. Cardiol.* 167(5), 2018–2023 (2013).

- Describes a study that demonstrates the use of multiplate electrode aggregometry in personalizing antiplatelet therapy.

27 Sibbing D, Koch W, Gebhard D et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. *Circulation* 121(4), 512–518 (2010).

28 Clinical trials database: NCT01959451. [https://clinicaltrials.gov/ct2/show](https://clinicaltrials.gov/ct2/show)

29 Stone GW, Witzenbichler B, Weisz G et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. *Lancet* 382(9892), 614–623 (2013).
• Describes a large prospective study associating high residual platelet reactivity in association with subsequent ischemic events.

30 Kirtane AJ, Parikh PB, Stuckey TD et al. Is there an ideal level of platelet P2Y$_{12}$ receptor inhibition in patients undergoing percutaneous coronary intervention? “window” analysis from the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). JACC Cardiovasc. Interv. 8(15), 1978–1987 (2015).

• This follow-up study (to [29]) associated low residual platelet reactivity in with subsequent bleeding events.

31 Patti G, Pascrei V, Vizzi V, Ricottini E, Di Sciascio G. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing npercutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty- Bleeding Study). Am. J. Cardiol. 107(7), 995–1000 (2011).

32 Rosengart TK, Romeiser JL, White LJ et al. Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration. J. Thorac. Cardiovasc. Surg. 146(5), 1259–1266 (2013).

33 Reed GW, Kumar A, Guo J et al. Point-ofcare platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: verify pre-op TIMI 45—a pilot study. Clin. Cardiol. 38(2), 92–98 (2015).

34 Price MJ, Berger PB, Teirstein PS et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11), 1097–1105 (2011).

35 Siller-Matula JM, Jilma B. Why have studies of tailored anti-platelet therapy failed so far? Thromb. Haemost. 110(4), 628–631 (2013).

36 Trenk D, Stone GW, Gawaz M et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J. Am. Coll. Cardiol. 59(24), 2159–2164 (2012).

37 Cayla G, Cuisset T, Silvain J et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 388(10055), 2015–2022 (2016).

38 Valgimigli M, Campo G, de Cesare N et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring
treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. *Circulation* 119(25), 3215–3222 (2009).

39 Campo G, Fileti L, de Cesare N et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. *J. Am. Coll. Cardiol.* 56(18), 1447–1455 (2010).

40 Fox SC, Sasae R, Janson S, May JA, Heptinstall S. Quantitation of platelet aggregation and microaggregate formation in whole blood by flow cytometry. *Platelets* 15(2), 85–93 (2004).

41 Heptinstall S, Espinosa DI, Manolopoulos P et al. DG-041 inhibits the EP3 prostanoid receptor-a new target for inhibition of platelet function in atherothrombotic disease. *Platelets* 19(8), 605–613 (2008).

42 Iyú D, Glenn JR, White AE, Fox SC, Heptinstall S. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y$_{12}$ antagonist. *Arterioscler. Thromb. Vasc. Biol.* 31(2), 416–422 (2011).

43 Iyú D, Glenn JR, White AE et al. Mode of action of P2Y(12) antagonists as inhibitors of platelet function. *Thromb. Haemost.* 105(1), 96–106 (2011).

44 van Werkum JW, Kleibeuker M, Postma S et al. A comparison between the Plateletwork-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. *Int. J. Cardiol.* 140(1), 123–126 (2010).

45 Holm M, Dalén M, Tornvall P, van der Linden J. Point-of-care testing of clopidogrel-mediated platelet inhibition and risk for cardiovascular events after coronary angiography with or without percutaneous coronary intervention. *Blood Coagul. Fibrinolysis* 25(6), 577–584 (2014).

46 Fox SC, May JA, Johnson A et al. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y$_{12}$ antagonist both in-vitro and ex vivo in human volunteers. *Platelets* 24(5), 392–400 (2013).

- Describes the use of platelet counting in combination with fixation as a means of assessing platelet reactivity in a remote location where no laboratory faculties were available.

47 Algahtani M, Dovlatova N, May J, Heptinstall S, Fox S. Flow cytometric measurement of platelet aggregation and platelet-leucocyte conjugate formation using small volume of fixed whole blood. *Platelets* 27(1), 2–3 (2016).

48 Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. *Curr. Opin. Hematol.* 6(5), 342–348 (1999).
49 Heptinstall S, Fox S, May J, White A, Dovlatova N. PAMFix, a fixative developed to enable remote platelet function testing. *Curr. Top. Pharmacol.* 19, 1–12 (2015).

- Describes the advantages of fixing platelets as a means of remote testing of platelet reactivity.

50 Dovlatova N, May JA, Fox SC. Remote platelet function testing – significant progress towards widespread testing in clinical practice. *Platelets* 26(5), 399–401 (2015).

51 Dovlatova N, Lordkipanidzé M, Lowe GC et al. Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders. *J. Thromb. Haemost.* 12(5), 660–665 (2014).

52 Dovlatova N, Lordkipanidzé M, Lowe GC et al. A reliable and simple diagnostic approach to detect platelet secretion defects in subjects with mucocutaneous bleeding. *J. Thromb. Haemostas.* 13(Suppl. S2), 929–930 (2015).

53 Thomas MR, Wijeyeratne Y, May JA, Johnson A, Heptinstall S, Fox SC. A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel. *Platelets* 25(8), 612–618 (2014).

54 Laohathai P, Joshi R, Radhakrishnan A et al. Residual platelet function in ACS patients treated with prasugrel is lower than in patients treated with clopidogrel but not in patients with hypertension. *J. Thromb. Haemostas.* 13(Suppl. 2), 518 (2015).

55 Heptinstall S, Dovlatova N, May J, Robson K, Bath P. Remote platelet function testing using measurements of P-selectin in patients with acute stroke or TIA already receiving treatment with antiplatelet agents. *J. Thromb. Haemostas.* 13(Suppl. 2), 695 (2015).

56 Keeler BD, Simpson JA, Fox SC et al. An observational study investigating the effect of platelet function on outcome after colorectal surgery. *Int. J. Surg.* 17, 28–33 (2015).

57 Adamany J, Dunning MD, May J, Fox S, Heptinstall S. Development and refinement of a remote platelet P-selectin test for measurement of platelet function in dogs and cats. *Platelets* 27, 1 (2016).

58 Furman MI, Barnard MR, Krueger LA et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. *J. Am. Coll. Cardiol.* 38(4), 1002–1006 (2001).

59 Zhao L, Fletcher S, Weaver C et al. Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. *Thromb. Haemost.* 93(3), 527–534 (2005).

60 Armstrong PC, Kirkby NS, Chan MV et al. Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet–monocyte interaction. *Blood* 126(10), e11–e18 (2015).
61 Ramström S, Södergren AL, Tynngård N, Lindahl TL. Platelet function determined by flow cytometry: new perspectives? *Semin. Thromb. Hemost.* 42(3), 268–281 (2016).

62 Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. *J. Thromb. Haemost.* 3(1), 85–92 (2005).

63 Varenhorst C, James S, Erlinge D et al. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. *Am. Heart J.* 157(3), 562.e1–569.e1 (2009).

64 Bonello L, Laine M, Camoin-Jau L et al. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in non-ST elevation acute coronary syndrome. *Thromb. Haemost.* 114(4), 702–707 (2015).

65 Danese E, Fava C, Beltrame F et al. Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry. *J. Thromb. Haemost.* 14(2), 282–293 (2016).

66 Glenn JR, Dovlatova N, White AE, Dhillon K, Heptinstall S, Fox SC. ‘VASPFix’ for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y<sub>12</sub> antagonists. *Thromb. Haemost.* 111(3), 539–548 (2014).

- Describes a one-step approach to the measurement of vasodilator-stimulated phosphoprotein phosphorylation as a means of measuring platelet reactivity.

67 Paniccia R, Antonucci E, Gori AM et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. *J. Thromb. Haemost.* 5(9), 1839–1847 (2007).

68 Dyszkiewicz-Korpanty A, Olteanu H, Frenkel EP, Sarode R. Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100). *Platelets* 18(7), 491–496 (2007).

69 Mueller T, Dieplinger B, Poelz W, Haltmayer M. Utility of the PFA-100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease. *Clin. Appl. Thromb. Hemost.* 15(6), 652–659 (2009).

70 Edwards A, Jakubowski JA, Rechner AR, Sugidachi A, Harrison P. Evaluation of the INNOVANCE PFA P2Y test cartridge: sensitivity to P2Y(12) blockade and influence of anticoagulant. *Platelets* 23(2), 106–115 (2012).

71 Koessler J, Kobzar AL, Rajkovic MS et al. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition. *Platelets* 22(1), 20–27 (2011).
72 Linnemann B, Schwonberg J, Rechner AR, Mani H, Lindhoff-Last E. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. *Ann. Hematol.* 89(6), 597–605 (2010).

73 Scavone M, Germanovich K, Femia EA, Cattaneo M. Usefulness of the INNOVANCE PFA P2Y test cartridge for the detection of patients with congenital defects of the platelet P2Y<sub>12</sub> receptor for adenosine diphosphate. *Thromb. Res.* 133(2), 254–256 (2014).

74 Kim H, Kim Y, Koh YS et al. Evaluation of the INNOVANCE PFA P2Y assay and its association with *CYP2C19* genotypes. *Platelets* 26(2), 148–153 (2015).

75 Li S, Choi JL, Guo LZ et al. Correlation between the *CYP2C19* phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy: an emphasis on newly introduced platelet function analyzer-200 P2Y test. *Ann. Lab. Med.* 36(1), 42–48 (2016).

76 Johnson A, Dovlatova N, Heptinstall S. Multiple electrode aggregometry and P2Y(12) antagonists. *Thromb. Haemost.* 99(6), 1127–1129 (2008).

77 Sumaya W, Joshi RR, Judge HM, Ecob R, Morton AC, Storey RF. Stability of VerifyNow P2Y12 assay results with citrate anticoagulation as compared with hirudin anticoagulation over 20-min period. *Platelets* 26(3), 271–273 (2015).

78 Gurbel PA, Bliden KP, Navickas IA et al. Adenosine diphosphate-induced plateletfibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. *Am. Heart J.* 160(2), 346–354 (2010).

79 Lv HH, Wu S, Liu X et al. Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China. *Neurol. Sci.* 37(2), 277–282 (2016).

80 Sambu N, Hobson A, Curzen N. “Short” thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: validation and reproducibility. *Platelets* 22(3), 210–216 (2011).

81 Sambu N, Radhakrishnan A, Dent H et al. Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry. *Heart* 98(9), 706–711 (2012).

82 Gurbel PA, Bliden KP, Tantry US et al. First report of the point-of-care TEG: a technical validation study of the TEG-6S system. *Platelets* 27(7), 642–649 (2016).

83 Berger PB, Kirchner HL, Wagner ES et al. Does preoperative platelet function predict bleeding in patients undergoing off pump coronary artery bypass surgery? *J. Interv. Cardiol.* 28(3), 223–232 (2015).
84 Cattaneo M. High on-treatment platelet reactivity-definition and measurement. *Thromb. Haemost.* 109(5), 792–798 (2013).

**Table 1**

**Approaches to assessment of platelet reactivity.**

Abbreviations: LTA: light transmission aggregometry; MEA: multiple electrode aggregometry; PFA: platelet function analyser; PRP: platelet-rich plasma; TEG: thrombelastography; VASP: vasodilator-stimulated phosphoprotein

| Approach                        | Method/equipment | Advantages                                                                                                                                         | Disadvantages                                                                                   |
|---------------------------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| LTA                             | Aggregometer     | Considered to be the gold standard. Formation of visible platelet aggregates accords with hemostatic plug and thrombus formation. Wide range of uses. | Performed in PRP. Centrifugation required. Platelet counts vary. Prompt access to laboratory facilities and technical expertise required. |
|                                 | Optimul assay    | 96-well format enables large number of samples to be assessed in parallel. Potential wide range of uses.                                            | As for LTA                                                                                      |
| Platelet aggregation in whole blood | MEA               | Use of whole blood considered to be more physiological than use of PRP. No centrifugation required. Wide range of uses.                              | Prompt access to laboratory facilities and technical expertise required                          |
|                                 | VerifyNow        | Use of whole blood considered to be more physiological than use of PRP. Measurements require availability of special equipment but                  | Specifically designed to monitor efficacy of antiplatelet agents and thus not designed for other uses. Disappointing clinical outcomes |


| Method                          | Example                  | Advantages                                                                 | Disadvantages                                                                 |
|--------------------------------|--------------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Platelet counting              |                          | minimal technical expertise is required. Point-of-care testing.             | when used to tailor treatment with antiplatelet agents.                       |
|                                |                          | Use of whole blood considered to be more physiological than use of PRP.     | A commercial version of the test (Plateletworks) requires immediate access to  |
|                                |                          | Fixation of blood samples can negate the need for immediate platelet counting and can enable remote testing. | equipment for platelet counting.                                              |
| Platelet activation markers    | Flow cytometry, e.g., P-selectin | Fixation of blood samples can negate the need for immediate flow cytometric analysis and can enable remote testing. No stirring or agitation of the blood is needed. Wide range of uses. | When used without fixation immediate access to flow cytometry facilities is required. |
|                                | Flow cytometry, e.g., platelet-leukocyte conjugates | Fixation of blood samples can negate the need for immediate flow cytometric analysis and can enable remote testing. A 96-well format can be used to agitate the blood samples. Wide range of uses. | When used without fixation immediate access to flow cytometry facilities is required. |
| Cell metabolites               | Flow cytometry, e.g., VASP phosphorylation | VASP phosphorylation reflects cyclic nucleotide levels in Platelets. Can be used to assess efficacy of P2Y12 | One approach (use of the Biocytex assay) requires immediate access to flow cytometry. |
Other approaches | PFA | An assay based on platelet adhesion to collagen under high shear. Measurements require availability of special equipment but minimal technical expertise is required. Point-of-care testing. The INNOVANCE PFA P2Y cartridge appears to provide an improved means of testing for effects of P2Y12 antagonists. | Further studies are needed with the INNOVANCE PFA P2Y cartridge to define the usefulness of the approach.  

| TEG | Deemed to provide a global test of thrombosis based on clot formation. Newer adaptations of the methodology show promise. | Further studies are needed to define the usefulness of the approach.  

| Aggreguide | Measurement of platelet aggregation based on light scattering technology. | Still in the early stages of Development.  

**Executive summary**

*Platelet reactivity: what is it & why study it?*

- Platelet reactivity is a broad term indicating the response of blood platelets to an external stimulus, usually an ‘aggregating agent’.  


Platelets play a role in the hemostatic process and also contribute to generation of a thrombus that can block a blood vessel leading heart attack or stroke.

A pronounced platelet response is associated with an increased risk of thrombosis and a low platelet response is associated with bleeding and bruising.

Detection of high residual platelet activity despite treatment with antiplatelet agents helps predict future ischemic events.

Identification of deficiencies in platelet function explains why some individuals are subject to enhanced bleeding or bruising.

Excessive inhibition of platelet reactivity in patients treated with antiplatelet agents can also be associated with excessive bleeding with implications for surgical interventions in those patients.

There is now the concept of using measurements of platelet reactivity to identify a ‘therapeutic window’ in patients receiving antiplatelet agents, so as to optimize a reduction in risk of a thrombotic event without increasing the risk of bleeding.

Approaches to assessment of platelet reactivity

- Measurement of platelet aggregation in platelet-rich plasma using light transmission aggregometry (LTA) is considered to be the ‘gold standard’ for measurement of reactivity but is complex and technically demanding.

- Measurement of platelet aggregation in whole blood using Multiplate Electrode Aggregometry (MEA), the VerifyNow approach and by platelet counting is deemed to be more physiological than studies performed in platelet-rich plasma.

- Measurement of platelet activation markers including P-selectin provides an alternative approach to measuring platelet reactivity and this introduces the concept of ‘remote’ platelet testing.

- Phosphorylation of vasodilator-stimulated phosphoprotein (VASP) provides another approach that has found value particularly in assessing the impact of P2Y12 antagonists on platelet reactivity. Methods based on measurements of platelet aggregation.

Light transmission aggregometry:

- Used in identifying deficiencies in platelet aggregation in association with enhanced bruising and bleeding.

- Used in quantitating the pharmacological effects of antiplatelet agents.
• There are positive examples of the use of LTA in determining the variable effects of the P2Y$_{12}$ antagonist clopidogrel and in considering the implications for re-thrombosis and bleeding.

Multiplate electrode aggregometry:

• Generally data obtained using MEA compare favorably with LTA.

• There are positive examples of the use of MEA for guiding antiplatelet therapy.

VerifyNow:

• Generally data obtained using VerifyNow compare favorably with LTA and MEA, and the advantage of VerifyNow is that little technical expertise is required.

• Clinical trials of using VerifyNow to guide the use of P2Y$_{12}$ antagonists as antiplatelet therapy have been unsuccessful so far in terms of improving clinical outcomes.

Platelet counting:

• Plateletworks provides a commercially available means of measuring platelet aggregation in whole blood by platelet counting and there are some positive comparisons with LTA.

• There are potential benefits of fixation of platelets prior to platelet counting that have already proved useful in platelet research.

Methods based on measurements of platelet activation markers

• Measurements of P-selectin as a means of studying platelet reactivity include studies in cardiology, stroke, surgery and veterinary medicine.

• The P-selectin approach offers the advantage of remote platelet testing with no need for a laboratory or special technical expertise available close to the point of blood testing.

• A consequence of P-selectin expression on platelets in whole blood is platelet–leukocyte conjugate formation, which can be quantified in parallel with measurements of platelet aggregation.

Methods based on measurements of a cell metabolite

• Measurement of the phosphorylation of VASP provides a convenient means of measuring the effects on platelets of agents that modify cyclic AMP, including P2Y$_{12}$ antagonists.

• The Biocytex approach involves permeabilizing platelets and measuring VASP-P by flow cytometry.
The VASPFix approach is a one-step approach that can be used remotely without the immediate availability of a flow cytometer.

**Additional approaches to assessing platelet reactivity**

- The platelet function analyzer (PFA)-100 is an easy-to-use device that is based on platelet adhesion to collagen.
- The introduction of the INNOVANCE PFA P2Y test cartridge for use in the PFA is being tested with some positive outcomes in assessment of the effects of ADP on platelets and the inhibitory effects of P2Y12 antagonists.
- Thrombelastography measures platelet-fibrin clot formation and has found some application in the studies of platelet reactivity.
- Newer approaches to thrombelastography are being introduced and assessed for measurement of platelet reactivity.
- Aggreguide is a new approach to testing that is based on the light scattering properties of aggregating platelets that is now starting to be assessed for its usefulness in the research and clinical practice.